Currently, Carcinoembryonic antigen (CEA) and CA125 are the commonly used tumor biomarkers in clinical practice for gastric cancer screening; early diagnosis, targeted treatment and prognosis are the main strategies to promote the five-year survival rate.2–5 However, the clinical diagnostic accuracy of CEA is unsatisfactory due to low sensitivity and specificity. This evidence concerns the gene CEACAM5 and neoplasm.